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Abstract Endothelin converting enzyme (ECE) is essential for generation of the biological effects of endothelin-1 (ET-l) from a precursor, big 
endothelin-1 (Big ET-l). We synthesized four analogs of human Big ET-1[16-381, substituted with single D-amino acids at Pl, P2, Pl’and P2’positions. 
ECE activity was determined using an ET-l specific radioimmunoassay system. None of the o-amino acid containing Big ET-l analogs were 
apparently cleaved by ECE, however, one of the synthetic peptides, [D-Va122]Big ET-1[1638], strongly inhibited the ECE activity. Furthermore, when 
this o-Val” containing peptide was preadministrated to rat striatum, it was found to inhibit the dopamine release induced by Big ET- 1. This result 
suggests that the o-Val” containing peptide inhibits the ECE activity in vivo. The D-Val” containing inhibitor offers hope of developing more potent 
and highly specific ECE inhibitors of therapeutic significance. 
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1. Introduction 
Endothelin-1 (ET-l) is a novel vasoconstrictor peptide con- 
sisting of 21 amino acid residues with two disulfide bonds [l]. 
During the biosynthetic process, prepro-endothelin-1 converts 
to the putative precursor, big endothelin-1 (Big ET-l), and then 
Big ET-l is processed by a novel endopeptidase, named endo- 
thelin converting enzyme (ECE) [1,2]. ET-l, Big ET-1 and the 
C-terminal fragment of Big ET-1 have all been detected in the 
culture medium [3] and plasma [4]. The in vitro vasoconstrictor 
activity of Big ET-l is much lower (>lOO-fold) than that of 
ET-l, but the in vivo pressor effects of the two peptides are 
comparable [5,6]. These findings support the hypothesis that 
generation of ET-1 by ECE is essential for the potent biological 
effects of this regulatory peptide system. Development of inhib- 
itors of ECE will provide effective means of preventing produc- 
tion of endothelin under pathogenic conditions [2,7]. 
Several ECE-like enzyme activities representing different en- 
dopeptidase classes have been identified. At first, a chymotryp- 
sin-like enzyme was suggested as a putative ECE [l]. Also 
cathepsin-like proteases have been considered as candidates for 
a putative ECE, but can only be induced under selective and 
unusual conditions [S]. The third class of enzymes as a putative 
ECE are neutral endopeptidases [9-131. These enzymes are 
sensitive to pH, and are inhibited by metal chelating agents, 
such as EDTA, and by phosphoramidon. The physiological 
relevance of a phosphoramidon-sensitive ECE activity is indi- 
cated by the findings that phosphoramidon also inhibits release 
of ET-l from endothelial cells [14]. 
Substitution with o-configuration amino acids in peptide li- 
gands has been widely used for probing the conformational 
requirements of ligand-receptor interactions. For example, the 
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low and high affinity receptors of atria1 natriuretic peptide can 
be distinguished by systematic D-amino acid replacements in 
the ligand [15]. A similar approach has been applied to studies 
of substrate-enzyme inhibitions. Substitution with o-amino 
acids in substrates for human spleen fibrinolytic protease and 
leukocyte elastase-like proteinase caused the specific inhibition 
of each or both enzymes [16,17]. Recently, short peptide deriv- 
atives of ET-l containing D-amino acid were prepared and 
found by others to be potent ET-l receptor antagonists [18-201. 
However, these studies on endothelin analogs did not include 
evaluation of their activities on ECE. Also, none of the many 
o-amino acid substituted endothelin peptide fragments encom- 
passed the length of Big ET-l, that is the subject of our study 
here. 
In this investigation, we synthesized the human Big ET-l 
analogs substituted with systematic single D-amino acids. These 
analogs were assayed for modulation of ECE activity. Of the 
four synthetic peptides, one peptide ([D-Val**]Big ET-1[1&38]) 
has shown potent inhibitory activity to the neutral ECE. This 
peptide was also found to inhibit the dopamine release induced 
by Big ET-l, in vivo. 
2. Materials and methods 
2.1. Synthesis of peptides 
The peptides were synthesized by the solid-phase method on a Bio- 
search automated peptide synthesizer Model 9600 based on t-buty- 
loxycarbonyl strategy. Deprotection and cleavage from the resin was 
achieved by the two-step method using trimethylsilyl bromide-thioani- 
sole and HF [21,22]. The crude peptides were purified by gel-filtration 
followed by reverse phase HPLC. The purity and identity of the pep- 
tides were confirmed by analytical HPLC and by amino acid analysis. 
Big ET-l, ET-1 and phosphoramidon were purchased from Peptide 
Institute Inc. (Osaka, Japan). 
2.2. Isolation of ECE 
Bovine aortic endothelial cells were prepared by the method de- 
scribed by Gospodarowicz et al. [23]. Confluent cells were washed with 
PBS and scraped in PBS by rubber policeman. Cells were homogenized 
followed by centrifugation at 100,000 x g for 1 h. After washing with 
All rights reserved. 
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PBS three times, the pellet was rehomogenized in PBS containing 1% 
CHAPS, and then stirred for 4 h. After centrifugation at 100,000 x g 
for 1 h, the supematant was concentrated by ultratiltration through a 
UK-10 fllter (Advantec Tokyo, at molecular weight cut-off 10,000). The 
concentrate was passed through a column of Immobilized Gvoinhibitor 
(Pierce, Rockford), in order to remove serine proteases. The resulting 
enzyme preparation was used for the assays. The activity of ECE in this 
preparation was stable during storage at -80°C for over 1 month 
(Okitsu, M. et al., unpublished data). 
2.3. Enzyme assay 
The enzyme preparation containing 0.2 mg protein was incubated 
with Bie ET-l at a concentration of 1 .O x lo-’ M for 2 h at 37°C in 20 
~1 of t& reaction mixture. The reaction mixture consisted of 50 mM 
HEPES, pH 7.0 and 2.5 mM N-ethyhnaleimide (NEM). NEM inhibits 
non-specific degradation of peptides produced by the ECE preparation 
[24]. After stopping the reaction by boiling at 1OO’C for 5 min, the 
resultant supematant was diluted 11100 and used directly for radioim- 
munoassay (RIA). In experiments testing the proteolytic activity of the 
enzyme on our synthetic peptides, substrate concentrations were kept 
at 1.0 x 10m5 M. In the evaluation of synthetic peptides as inhibitors the 
enzyme fraction was co-incubated with 1 .O x lo-’ M of Big ET-l and 
1 .O x lo-’ M of each synthetic peptide. In the kinetic experiments, both 
the concentration of Big ET-l and synthetic peptides were varied. One 
unit of enzyme activity is the quantity which catalize the formation of 
1 pmol of the product per hour at 37’C. Protein concentrations were 
determined with the Micro BCA Protein Assay Reagent (Pierce, Rock- 
ford) [25], and bovine serum albumin as standard. 
2.4. Radioimmunoassay (RIA) for ET-I 
RIA was performed as described by Ando et al. [26], with some 
modifications. The assay buffer for RIA was 0.01 M phosphate buffer, 
pH 7.4, containing 0.14 M NaCl, 0.01 M EDTA, 0.02 M glycine, 0.01 
M s-aminocaproic acid, 1 mM sodium azide, 0.1 mg/ml human serum 
albumin (Sigma), and 0.1% Triton X-100. This assay buffer was used 
to dissolve all reagents. The incubation mixture consisted of 0.1 ml 
sample or standard solution, 0.1 ml assay buffer, 0.1 ml anti-lys-lys- 
ET[15-211 antisermn (final dilution; 1:30,000 - Immuno Biological 
Laboratories (Gumma, Japan)), 0.1 ml of 0.185 kBq of [“‘I]ET-1 (74 
TBq/mmol, Amersham) and 1~1 of normal rabbit serum (Calbiochem). 
Incubations were carried out at 4°C for 24 h. In order to separate the 
bound ligands from the free ones, 0.1 ml of 5 units/ml goat anti-rabbit 
y-globulin was added following the incubation at 4°C for 4 h. After 
centrifugation at 10,000 x g for 5 min, the radioactivity in the precipi- 
tate was measured by y-counter. The amount of immunoreactive-pep- 
tide in the unknown sample was extrapolated from the standard curve 
linearized by a logit-log transformation. In order to compare our RIA 
system to that used by Ando et al. [26], we also used the antiserum 
provided from them. 
Peptide Name i Amino Acid Sequences 
2.5. Measurement of abpamine release from the striatum 
Male Wistar rats 25&350 g were anesthetized and the guide cannula 
for penetration of microdialysis probe into the striatum was stereotax- 
ically implanted as described by Paxinos and Watson [271. After allow- 
ing at least three days for recovery from the surgery, microdialysis 
experiments were carried out with a freely moving rat placed in a acrylic 
home cage. On the day before the dialysis experiment, the dummy 
cammla was removed from the guide cammla, and the dialysis probe 
was inserted into the guide cannula. This dialysis probe (MI-BDP-1-8- 
03, Eicom, Japan) had a dialysis membrane (at molecular weight cut-off 
5,ooO) and a side tube in order to microinject sample from outside. The 
probe was perfused with the Ringer solution (147 mM Na+, 4 mM K’, 
2.3 mM Ca’+. and 155.6 mM Cl-, pH 6.0) at a rate of Z@/min (EP-60; 
Eicom, Japan). In order to observe the effect of Big ET-l, phospho- 
ramidon and EV-D, 10 jd of sample were microinjected via the side 
tube. 
The releasable dopamine (DA) was separated by the reverse-phase 
HPLC using MA-ODS Colmnn (5 pm particles, diam. 4.6 x 250 mm; 
Eicom, Japan) and detected with electrochemical detector (CB-100; 
Eicom, Janan). The mobile uhase was cornnosed bv 0.1 M citric acid 
buffer,’ pH‘ 3.9, containing 15% methanol, i60 rng/i sodium-l-octane- 
sulfate and 20 mM EDTA. The graphite lectrode (WE3G, Eicom, 
Japan) was set at +0.65 V (vs. Ag/AgCl). The perfusate from the 
striatum (40 ~1) was injected into the HPLC every 20 min by an auto- 
matic injector (AS-IO; Eicom, Japan). The level of DA was expressed 
as% of the basal evel. 
3. Resuks and discussion 
3.1. Synthetic peptides 
We previously reported the method for the synthesis of Big 
ET- 1 [l-38] and related peptides [22]. Utilizing this method, we 
synthesized several peptides listed in Fig. 1. Since Big ET-l 
contains 2 specific disulfide bonds and a long C-terminal seg- 
ment, synthesis of numerous analogs poses a cumbersome chal- 
lenge. Therefore, the design of shorter yet still suitable cleavage 
site segments are advantageous. However, Wu-Wong et al. 
found that a neutral ECE did not cleave a decapeptide substrate 
that contains five amino acids on both sides of the scissile bond 
[12]. This suggested that portions of the substrate sequence far 
removed from the scissile bond may be essential for enzyme 
recognition. Okada et al. [13] reported that the C-terminal 
residues 27-34 of Big ET-l are important for conversion by a 
neutral ECE from bovine endothelial cells. This region may be 
critical for enzyme recognition. They also found that Big 
16 1 21 22 1 25 35 38 
ET-L: BigET-1(16-38); 
EI-D:[D-Ile20]BigET-l(16-38); 
EW-D:[D-Trpzl]BigET-1(16-38); 
EV-D:[D-Va12*]BigET-1(16-38); 
EN-D:[D-Asn23]BigET-l(16-38); 
Fig. 1. Amino acid sequences of synthetic peptides. Each amino acid is shown by a one-letter symbol and o-amino acid shown by small letters are 
underlined. The bracketed region indicates the scissile bond of each peptide, which is cleaved by ECE. 
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Fig. 2. Cross-reactivity of the synthetic peptides to antiserum. Each curve was constructed using BIB, vs. logA4 for each synthetic peptide. Vertical 
bars indicate means + S.D. (n = 3). 
ET-l[ 16-371 has a high sensitivity to a neutral ECE [ 131. There- 
fore, we chose to synthesize ET-L (Big ET-1[16-38]), a 23-mer, 
as a suitable substrate for a neutral ECE, which has shorter 
length than Big ET-1 and does not contain disulfide bonds. We 
also prepared another four ET-L analogs substituted with sys- 
tematic single D-amino acid replacement, such as EI-D ([D- 
IleTBig ET-1[16-38]), EW-D ([n-Trp*‘]Big ET-1[16-38]), 
EV-D ([D-Val*]Big ET-l [16-38]), and EN-D ([n-Asnz3]Big 
ET-1[16-381). Other peptides listed in Fig. 1 are fragments of 
peptides described above, which are the expected cleavage 
products by the neutral ECE. 
3.2. Radioimmunoassay 
The RIA system in this investigation was the same as de- 
scribed by Ando et al. [26], and the titer and specificity of 
antiserum was also the same (data not shown). Antiser- 
um against Lys-Lys-ET[15-211 recognized the sequence of 
Big ET-1 ET-L El-D EW-D EV-D EN-D 
Substrates 
Fig. 3. Cleavage of Big ET-l analogs by Immobilized Ovoinhibitor 
purified ECE. Peptide substrate concentration: 1.0 x 10e5 M. To deter- 
mine the concentration of the hydrolyzed fragments, standard curves 
were used for each peptide: ET-l for Big ET-l, [n-Ile20]ET-1[16-211 
for EI-D, [D-Trp”]ET-1[16-211 for EW-D and ET-1[1&21] for EV-D, 
EN-D and ET-L. Vertical bars indicate means -I S.D. (n = 3). 
ET[15-211 including the free C-terminal Trp residue. Im- 
munoreactivities of the synthetic peptides were determined 
using our antiserum (Fig. 2). The detection limit of ET-l and 
Big ET-l was 2.5 x 10-i’ M and 2.5 x lo-’ M, respectively. The 
immunoreactivity of ET-L to our antiserum was less potent 
(1 .O x 10e6 M) than that of Big ET- 1. The four Big ET- 1 analogs 
substituted with b-amino acids (EI-D, EW-D, EV-D and 
EN-D) reacted with our antiserum only at the concentrations 
higher than 1.0x 10m5 M. The other peptides (ET-1[16-211, 
[n-IleZO]ET-1[16-211 and [D-Trp*‘]ET-1[16-211) are putative 
fragments after ECE digestion of ET-L, EI-D and EW-D. 
ET-1[16-211 was immunoreactive at the concentration of more 
than 5 x lo-” M. This immunoreactivity is comparable to that 
of ET-l. [D-IleTET-1[16-211 and [D-Trp21]ET-1[16-21] were 
immunoreactive at concentrations of more than 1.0 x lo-’ M 
and 2.5 x lo-’ M, respectively. We determined the appropriate 
peptide concentrations in the enzyme assays on the basis of 
results in Fig. 2. 
3.3. Inhibition of ECE by synthetic peptides 
The various shortened Big ET-l analogs were evaluated as 
substrates for the enzyme. ET-L was found to be cleaved effi- 
ciently, as measured by RIA (Fig. 3). In this case, the im- 
munoreactive-peptide is most probably ET-1[16-211. The four 
D-amino acid containing human Big ET-1 analogs (EI-D, EW- 
D, EV-D and EN-D) were not converted to the immunoreac- 
tive-peptide by ECE (Fig. 3). These result suggest hat ECE 
does not cleave Big ET-l analogs substituted by D-amino acid 
at the Pl, P2, Pl’ and P2’ positions. 
The ECE activity of the Immobilized Ovoinhibitor column 
purified enzyme was inhibited by EDTA, a metal chelator, and 
by phosphoramidon, a neutral protease inhibitor (Fig. 4). 
These results confirmed the previous findings of others [9-l 11. 
Our kinetic studies of the enzyme, using Big ET-l as the sub- 
strate, yielded a K, of 6.9 x 10e6 M and I’,, of 189 units/mg 
protein. These properties of the enzyme were very similar to 
those obtained by Ohnaka et al. [9]. Therefore, our ECE activ- 
ities detected in this investigation also result from the existence 
of a phosphoramidon-sensitive neutral metal protease. 
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The ECE activity was apparently inhibited by all four human 
Big ET-l analogs substituted with systematic single o-amino 
acids (ELD, EW-D, EV-D and EN-D), at the concentration of 
1.0 x 10e3 M (Fig. 4). EN-D showed the weakest inhibitory 
activity, although EI-D and EW-D apparently inhibited the 
ECE activity (Fig. 4). EV-D showed the strongest inhibitory 
activity with an apparent 85% inhibition of enzyme activity 
(Fig. 4). We performed kinetic studies using EV-D and found 
that it acted through a competitive mode of inhibition mecha- 
nism with apparent Ki value of approximately 2.5 x lo-’ M. 
3.4. Inhibition of dopamine release in vivo 
It has been postulated that ET-l may function as neuropep- 
tide in controlling of neural function [2]. Using microdialysis 
technique, which is a new technique to monitor levels of chem- 
ical agents in the extracellular space [28], Kurosawa et al. was 
reported that ET-l induced dopamine (DA) release from the 
striatum of rats [29]. Recently, we suggested that ET-1 directly 
induced the dopamine release (Horie, K. et al., unpublished 
data). When Big ET-1 (50 pmol) was microinjected into the rat 
striatum, the DA release from the striatum was dramatically 
increased to 17,000% of the basal level (Fig. 5). However, when 
10 pmol of phosphoramidon was preinjected, the DA release 
by Big ET-l was inhibited (Fig. 5). The dose for 50% inhibiton 
of this effect of phosphoramidon is about 1.5 pmol. These 
results suggest hat Big ET-1 is converted to ET-1 by ECE in 
the rat striatum, and the produced ET-1 increases the DA 
release. Our new potent ECE inhibitor, EV-D, was found to 
inhibit the DA release induced by Big ET-l (Fig. 5). The dose 
for 50% inhibiton of this effect of EV-D is about 0.33 pmol. 
These parallel results implicate that EV-D inhibits ECE in the 
rat striatum, prevents the production of ET-l, and thus abol- 
ishes the inducing DA release. 
In this paper, we have shown that EV-D, [D-Val”]Big ET- 
1[16-381, inhibits the ECE activity in in vitro and in vivo exper- 
iments. These inhibitory effects of EV-D were comparable with 
those of phosphoramidon. Phosphoramidon has the phos- 
phoryl-Leu moiety, which contributes the majority of its bind- 
ing energy to the enzyme. Many enzymes, such as thermolysin 
and neutral endopeptidase 24.11, are inhibited by phospho- 
g- 50 
m 1 
“one EDTA Phcepho El-D EW-D EV-D EN-D 
lnhibiiors 
Fig. 4. Inhibitory effect of Big ET-l analogs containing n-amino acid 
on ECE activity. Concentration of phosphoramidon and EDTA was 
0.25 mM and 0.125 mM, respectively. Concentration of each Big ET-l 
analog was 1.0 x lo-’ M in the enzyme assay. Vertical bars indicate 
means + SD. (n = 3). 
Ringer Phosphoramidon EV-D 
Preadmlnistration 
Fig. 5. EV-D suppresses the Big ET-l induced dopamine release from 
the striatmn of rat. At one hour after pre-administration of Ringer, 
phosphoramidon (10 pmoYl0 ~1 Ringer), or EV-D (1 pmoVl0 ~1 
Ringer), Big ET-l (50 pmoYlOp1 Ringer) was microinjected. Averaged 
values of DA contents at 20,40, 60 and 80 min were expressed as % 
of the basal levels. Vertical bars indicate means + S.D. (n = 4 for 
Ringer, n = 1 for phosphoramidon, n = 3 for EV-D). 
ramidon [2]. On the other hand, EV-D may be bound to ECE 
through specific peptide chain interactions, including amino 
acid residues 27-34 [ 131, but cannot be hydrolyzed at the scissile 
site. These suggest hat EV-D is a more specific ECE inhibitor 
compared to phosphoramidon. EV-D is potentially a useful 
ECE inhibitor for studying biological role and mechanism of 
endothelin precursors. Structure-activity relationship studies 
of EV-D will be expected to produce stronger and more specific 
ECE inhibitors of therapeutic significance. 
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